NOTE: this blog comes from an interview conducted with IDRI’s Rob Lin by Claire Topal of the National Bureau of Asian Research.
Around 20 years ago, researchers and funders realized that there was a need to create health solutions for diseases of the poor in developing countries, and that this need wasn’t necessarily being (or going to be) addressed by pharmaceutical companies given existing market mechanisms. Product Development Partnerships (PDPs) were created as a tool for donors and governments to fund projects that would address some of these inequities and reduce or even remove the risk for pharmaceutical companies to be engaged in the process.
The way PDPs work is similar to drug and vaccine development in the pharmaceutical sector. The main differences are that funding doesn’t come from private sources but rather from public sources—either governments or large foundations—with the goal of developing health solutions for diseases of the developing world that don’t have a large market potential. (more…)